High-performance liquid chromatographic assay for the novel antitumor drug, bryostatin-1, incorporating a serum extraction technique.
Authors
Khan, ParveenMcGown, Alan T
Dawson, Martin J
Jayson, Gordon C
Prendiville, Joseph A
Pettit, G R
Crowther, Derek
Affiliation
CRC Department of Experimental Chemotherapy, Paterson Institute for Cancer Research, Christie CRC Cancer Centre, Manchester, UK.Issue Date
1998-05-08
Metadata
Show full item recordAbstract
An HPLC assay incorporating a solid-phase extraction technique has been devised for bryostatin-1. Quantitation of bryostatin was found to be linear over the concentration range 0.012-25 microg/ml (0.2-25 ng on column) and was found to have a limit of detection of 0.2 ng on column, with a correlation coefficient of 0.9999. Following extraction of bryostatin over a range of concentrations from horse serum (0.012-25 microg/ml) and human serum (0.01-0.32 microg/ml) using a 100-mg C18 solid-phase extraction cartridge, extraction efficiencies consistently greater than 90% were obtained for extraction from horse serum and varied between 57 and 85% from human serum. However, on extending this work to blood samples from patients undergoing therapy with bryostatin-1, the drug was not detectable even at the maximum dose given, demonstrating the rapid loss of this agent from peripheral circulation.Citation
High-performance liquid chromatographic assay for the novel antitumor drug, bryostatin-1, incorporating a serum extraction technique. 1998, 709 (1):113-7 J. Chromatogr. B Biomed. Sci. Appl.Journal
Journal of Chromatography. B, Biomedical Sciences and ApplicationsDOI
10.1016/S0378-4347(98)00007-3PubMed ID
9653932Type
ArticleLanguage
enISSN
1387-2273ae974a485f413a2113503eed53cd6c53
10.1016/S0378-4347(98)00007-3